ClinicalTrials.gg
Active, not recruitingNCT04732871Updated Sep 28, 2026Results posted

Immunogenicity, Safety, Reactogenicity and Persistence of an Investigational Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 60 Years and Above

A Phase 3 interventional study of RSVPreF3 OA investigational vaccine in Respiratory Syncytial Virus Infections, sponsored by GlaxoSmithKline. Active, not recruiting at 46 sites in 5 countries. Open to participants aged 60 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-28.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Prevention

Updated Sep 28, 20263 sites added3 sites removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,720
Allocation
Randomized
Ages
60 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 17 studies testing arexvy in Respiratory Syncytial Virus Infections — 1 open to participants now, 5 under way, 4 of them phase 3. arexvy · Respiratory Syncytial Virus Infections.

Enrollment
4th of 17
1,720 · median 976
Started
2021
with 3 others
Phase 3
15 of 17
none open now
Registered
1st of 17
by date
Lead sponsor
15 of 17
GlaxoSmithKline

Among the 17 studies testing arexvy in Respiratory Syncytial Virus Infections, this one is the 4th largest by enrollment, is one of 4 that started in 2021, is one of 15 in phase 3, and was the 1st registered.

Respiratory Syncytial Virus Infections

306 studies on the registry are indexed under Respiratory Syncytial Virus Infections; 49 are open to participants now.

Browse Respiratory Syncytial Virus Infections studies →

Open to participants now

1 of the 17 studies testing arexvy in Respiratory Syncytial Virus Infections is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About arexvy

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 29 Respiratory Syncytial Virus Infections studies recruiting now, 14 (48%) set no upper age limit and 11 (38%) stop at 75 or younger; 13 take children under 18; 8 take healthy volunteers.

This study: 60 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing arexvy in Respiratory Syncytial Virus Infections, or all of them as a file.
02

Study summary

The purpose of this study is to assess the safety, reactogenicity, immunogenicity and long-term persistence of immune response up to 5 years following a single dose vaccination of GSK's investigational vaccine RSVPreF3 OA, in adults aged 60 years and above. The study will also evaluate the immunogenicity, safety and reactogenicity of additional vaccine doses given according to different revaccination schedules.

03

Conditions studied

  • Respiratory Syncytial Virus Infections

Keywords

  • Respiratory syncytial virus
  • Vaccine
  • Safety
  • Reactogenicity
  • Immunogenicity
04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female participants ≥60 YOA at first vaccination, who live in the community (CD participants) or in a Long-term care facility (LTCF participants).
  • Participants who, in the opinion of the investigator, can and will comply with the requirements of the protocol.
  • Written or witnessed obtained from the participant prior to performance of any study specific procedure.
  • Participants who are medically stable in the opinion of the investigator at the time of first vaccination. Patients with chronic stable medical conditions with or without specific treatment, such as diabetes, hypertension or cardiac disease, are allowed to participate in this study if considered by the investigator as medically stable.

Exclusion criteria

Exclusion Criteria:

Medical conditions

  • Any confirmed or suspected or immunodeficient condition resulting from disease or immunosuppressive/cytotoxic therapy, based on medical history and physical examination.
  • History of any reaction or likely to be exacerbated by any component of the vaccine.
  • Hypersensitivity to latex.
  • Serious or unstable chronic illness.
  • Recurrent or un-controlled neurological disorders or seizures. Participants with medically-controlled active or chronic neurological diseases can be enrolled in the study as per investigator assessment, provided that their condition will allow them to comply with the requirements of the protocol.
  • Significant underlying illness that in the opinion of the investigator would be expected to prevent completion of the study.
  • Any medical condition that in the judgment of the investigator would make intramuscular injection unsafe.
  • Any history of dementia or any medical condition that moderately or severely impairs cognition.

Prior/Concomitant therapy

  • Use of any or non-registered product other than the study vaccine during the period beginning 30 days before the first dose of study vaccine, or planned use during the study period.
  • Planned or actual administration of a vaccine not foreseen by the study protocol in the period starting 30 days before each dose and ending 30 days after each dose of study vaccine administration, with the exception of inactivated, split virion and subunit influenza vaccines which can be administered up to 14 days before or from 14 days after each study vaccination.
  • Previous vaccination with an RSV vaccine.
  • Administration of long-acting immune-modifying drugs or planned administration at any time during the study period.
  • Administration of immunoglobulins and/or any blood products or plasma derivatives during the period starting 90 days before the first dose of study vaccine or planned administration during the study period.
  • Chronic administration (defined as more than 14 consecutive days in total) of immunosuppressants or other immune-modifying drugs during the period starting 90 days prior to the first vaccine dose or planned administration during the study period. For , this will mean prednisone >=20 mg/day, or equivalent. Inhaled and topical steroids are allowed.

Prior/Concurrent clinical study experience

  • Concurrently participating in another clinical study, at any time during the study period, in which the participant has been or will be exposed to an investigational or a non-investigational vaccine/product.

Other exclusions

  • History of chronic alcohol consumption and/or drug abuse as deemed by the investigator to render the potential participant unable/unlikely to provide accurate safety reports or comply with study procedures.
  • Bedridden participants.
  • Planned move during the study period that will prohibit participation in the trial until the study end. This includes:
  • Planned move during the study period to another LTCF that will prohibit participation in the trial until study end.
  • Planned move from the community to a LTCF that will prohibit participation in the trial until study end.
  • Participation of any study personnel or their immediate dependants, family, or household members.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,720 participants (actual)

Study arms

  • Experimental
    RSV_annual Group

    Participants receive one dose of RSVPreF3 OA investigational vaccine at Day 1 and 2 revaccination doses at 12 months post-Dose 1 and at 24 months post-Dose 1, respectively and are followed up until Month 60.

    Biological: RSVPreF3 OA investigational vaccine

  • Experimental
    RSV_Flexible revaccination Group

    Participants receive one dose of RSVPreF3 OA investigational vaccine at Day 1 and 2 revaccination doses at 24 months post-Dose 1 and at 48 months post-Dose 1, respectively and are followed up until Month 60.

    Biological: RSVPreF3 OA investigational vaccine

  • Experimental
    RSV_1dose Group

    Participants receive one dose of RSVPreF3 OA investigational vaccine at Day 1 and are followed up until Month 36. At Month 36, participants in this group will be re-randomized in 2 groups: RSV\_1dose\_M36 (which will receive 1 additional revaccination dose at Month 36 and will be followed up until Month 60) and RSV\_1dose\_Flexible (which will receive 1 additional revaccination dose at Month 60, and will be followed up until study end at Month 72).

    Biological: RSVPreF3 OA investigational vaccine

Interventions

06

What researchers measure

Primary outcomes

  1. Humoral Immune Response in Terms of Respiratory Syncytial Virus (RSV)-A Neutralizing Antibody Geometric Mean Titers (GMTs) at Day 1

    RSV-A neutralizing antibodies were given as GMTs and expressed as Estimated Dose: serum dilution giving a 60% reduction of the RSV plaques compared to a control without serum (ED60).

    Time frame: At Day 1

  2. Humoral Immune Response in Terms of RSV-A Neutralizing Antibody GMTs at Day 31

    RSV-A neutralizing antibodies were given as GMTs and expressed as ED60.

    Time frame: At Day 31

  3. Humoral Immune Response in Terms of RSV-A Neutralizing Antibody GMTs at Month 6

    RSV-A neutralizing antibodies were given as GMTs and expressed as ED60.

    Time frame: At Month 6

  4. Humoral Immune Response in Terms of RSV-A Neutralizing Antibody GMTs at Month 12

    RSV-A neutralizing antibodies were given as GMTs and expressed as ED60.

    Time frame: At Month 12

  5. Humoral Immune Response in Terms of RSV-B Neutralizing Antibody Titers at Day 1

    RSV-B neutralizing antibodies measured as GMTs and expressed as ED60.

    Time frame: At Day 1

  6. Humoral Immune Response in Terms of RSV-B Neutralizing Antibody Titers at Day 31

    RSV-B neutralizing antibodies measured as GMTs and expressed as ED60.

    Time frame: At Day 31

  7. Humoral Immune Response in Terms of RSV-B Neutralizing Antibody Titers at Month 6

    RSV-B neutralizing antibodies measured as GMTs and expressed as ED60.

    Time frame: At Month 6

  8. Humoral Immune Response in Terms of RSV-B Neutralizing Antibody Titers at Month 12

    RSV-B neutralizing antibodies measured as GMTs and expressed as ED60.

    Time frame: At Month 12

Secondary outcomes

  1. Humoral Immune Response in Terms of RSVPreF3 Immunoglobulin G (IgG) Antibody Geometric Mean Concentrations (GMCs) at Day 1

    Serological assays for the determination of IgG antibodies against RSV PreF3 are performed by enzyme-linked immunosorbent assay (ELISA). The corresponding antibody GMC was expressed in Elisa Laboratory Units/milliliter (ELU/mL).

    Time frame: At Day 1

  2. Humoral Immune Response in Terms of RSVPreF3 IgG Antibody GMCs at Day 31

    Serological assays for the determination of IgG antibodies against RSV PreF3 are performed by ELISA. The corresponding antibody GMC was expressed in ELU/mL.

    Time frame: At Day 31

  3. Humoral Immune Response in Terms of RSVPreF3 IgG Antibody GMCs at Month 6

    Serological assays for the determination of IgG antibodies against RSV PreF3 are performed by ELISA. The corresponding antibody GMC was expressed in ELU/mL.

    Time frame: At Month 6

  4. Humoral Immune Response in Terms of RSVPreF3 IgG Antibody GMCs at Month 12

    Serological assays for the determination of IgG antibodies against RSV PreF3 are performed by ELISA. The corresponding antibody GMC was expressed in ELU/mL.

    Time frame: At Month 12

  5. Humoral Immune Response in Terms of RSV-A Neutralizing Antibody GMTs at Month 18

    Month 18 data will be disclosed during final posting. RSV-A neutralizing antibodies were given as GMTs and expressed as Estimated Dose: serum dilution giving a 60% reduction of the RSV plaques compared to a control without serum (ED60).

    Time frame: At Month 18

  6. Humoral Immune Response in Terms of RSV-A Neutralizing Antibody GMTs at Month 24

    Month 24 data will be disclosed during final posting. RSV-A neutralizing antibodies were given as GMTs and expressed as Estimated Dose: serum dilution giving a 60% reduction of the RSV plaques compared to a control without serum (ED60).

    Time frame: At Month 24

  7. Humoral Immune Response in Terms of RSV-A Neutralizing Antibody GMTs at Month 30

    Month 30 data will be disclosed during final posting. RSV-A neutralizing antibodies were given as GMTs and expressed as Estimated Dose: serum dilution giving a 60% reduction of the RSV plaques compared to a control without serum (ED60).

    Time frame: At Month 30

  8. Humoral Immune Response in Terms of RSV-A Neutralizing Antibody GMTs at Month 36

    Month 36 data will be disclosed during final posting. RSV-A neutralizing antibodies were given as GMTs and expressed as Estimated Dose: serum dilution giving a 60% reduction of the RSV plaques compared to a control without serum (ED60).

    Time frame: At Month 36

  9. Humoral Immune Response in Terms of RSV-A Neutralizing Antibody GMTs at Month 13

    Month 13 data will be disclosed during final posting. RSV-A neutralizing antibodies were given as GMTs and expressed as Estimated Dose: serum dilution giving a 60% reduction of the RSV plaques compared to a control without serum (ED60).

    Time frame: At Month 13

  10. Humoral Immune Response in Terms of RSV-A Neutralizing Antibody GMTs at Month 25

    Month 25 data will be disclosed during final posting. RSV-A neutralizing antibodies were given as GMTs and expressed as Estimated Dose: serum dilution giving a 60% reduction of the RSV plaques compared to a control without serum (ED60).

    Time frame: At Month 25

  11. Humoral Immune Response in Terms of RSV-B Neutralizing Antibody Titers at Month 18

    Month 18 data will be disclosed during final posting. RSV-B neutralizing antibodies were given as GMTs and expressed as Estimated Dose: serum dilution giving a 60% reduction of the RSV plaques compared to a control without serum (ED60).

    Time frame: At Month 18

  12. Humoral Immune Response in Terms of RSV-B Neutralizing Antibody Titers at Month 24

    Month 24 data will be disclosed during final posting. RSV-B neutralizing antibodies were given as GMTs and expressed as Estimated Dose: serum dilution giving a 60% reduction of the RSV plaques compared to a control without serum (ED60).

    Time frame: At Month 24

  13. Humoral Immune Response in Terms of RSV-B Neutralizing Antibody Titers at Month 30

    Month 30 data will be disclosed during final posting. RSV-B neutralizing antibodies were given as GMTs and expressed as Estimated Dose: serum dilution giving a 60% reduction of the RSV plaques compared to a control without serum (ED60).

    Time frame: At Month 30

  14. Humoral Immune Response in Terms of RSV-B Neutralizing Antibody Titers at Month 36

    Month 36 data will be disclosed during final posting. RSV-B neutralizing antibodies were given as GMTs and expressed as Estimated Dose: serum dilution giving a 60% reduction of the RSV plaques compared to a control without serum (ED60).

    Time frame: At Month 36

  15. Humoral Immune Response in Terms of RSV-B Neutralizing Antibody Titers at Month 13

    Month 13 data will be disclosed during final posting. RSV-B neutralizing antibodies were given as GMTs and expressed as Estimated Dose: serum dilution giving a 60% reduction of the RSV plaques compared to a control without serum (ED60).

    Time frame: At Month 13

  16. Humoral Immune Response in Terms of RSV-B Neutralizing Antibody Titers at Month 25

    Month 25 data will be disclosed during final posting. RSV-B neutralizing antibodies were given as GMTs and expressed as Estimated Dose: serum dilution giving a 60% reduction of the RSV plaques compared to a control without serum (ED60).

    Time frame: At Month 25

  17. Humoral Immune Response in Terms of RSVPreF3 IgG Antibody GMCs at Month 18

    Month 18 data will be disclosed during final posting. Serological assays for the determination of IgG antibodies against RSV PreF3 were performed by ELISA. The corresponding antibody GMC was expressed in ELU/mL.

    Time frame: At Month 18

  18. Humoral Immune Response in Terms of RSVPreF3 IgG Antibody GMCs at Month 24

    Month 24 data will be disclosed during final posting. Serological assays for the determination of IgG antibodies against RSV PreF3 were performed by ELISA. The corresponding antibody GMC was expressed in ELU/mL.

    Time frame: At Month 24

  19. Humoral Immune Response in Terms of RSVPreF3 IgG Antibody GMCs at Month 30

    Month 30 data will be disclosed during final posting. Serological assays for the determination of IgG antibodies against RSV PreF3 were performed by ELISA. The corresponding antibody GMC was expressed in ELU/mL.

    Time frame: At Month 30

  20. Humoral Immune Response in Terms of RSVPreF3 IgG Antibody GMCs at Month 36

    Month 36 data will be disclosed during final posting. Serological assays for the determination of IgG antibodies against RSV PreF3 were performed by ELISA. The corresponding antibody GMC was expressed in ELU/mL.

    Time frame: At Month 36

  21. Humoral Immune Response in Terms of RSVPreF3 IgG Antibody GMCs at Month 13

    Month 13 data will be disclosed during final posting. Serological assays for the determination of IgG antibodies against RSV PreF3 were performed by ELISA. The corresponding antibody GMC was expressed in ELU/mL.

    Time frame: At Month 13

  22. Humoral Immune Response in Terms of RSVPreF3 IgG Antibody GMCs at Month 25

    Month 25 data will be disclosed during final posting. Serological assays for the determination of IgG antibodies against RSV PreF3 were performed by ELISA. The corresponding antibody GMC was expressed in ELU/mL.

    Time frame: At Month 25

  23. Cell-Mediated Immunity (CMI) Response in Terms of Frequency of RSVPreF3-specific Cluster of Differentiation CD4 atl2_7m T Cells Expressing at Least 2 Activation Markers at Day 1

    Among markers expressed were interleukin-2/13/17 (IL2, IL13, IL17), cluster of 40 ligand (CD40L), 41BB, tumor necrosis factor alpha (TNF α) and interferon gamma (IFN γ), in vitro upon stimulation with RSVPreF3 peptide preparations.

    Time frame: At Day 1

  24. CMI Response in Terms of Frequency of RSVPreF3-specific CD8 atl2_7m T Cells Expressing at Least 2 Activation Markers at Day 1

    Among markers expressed were IL2, IL13, IL17, CD40L, 41BB, TNF α and IFN γ, in vitro upon stimulation with RSVPreF3 peptide preparations.

    Time frame: At Day 1

  25. CMI Response in Terms of Frequency of RSVPreF3-specific CD4 atl2_7m T Cells Expressing at Least 2 Activation Markers at Day 31

    Among markers expressed were IL2, IL13, IL17, CD40L, 41BB, TNF α and IFN γ, in vitro upon stimulation with RSVPreF3 peptide preparations.

    Time frame: At Day 31

  26. CMI Response in Terms of Frequency of RSVPreF3-specific CD8 atl2_7m T Cells Expressing at Least 2 Activation Markers at Day 31

    Among markers expressed were IL2, IL13, IL17, CD40L, 41BB, TNF α and IFN γ, in vitro upon stimulation with RSVPreF3 peptide preparations.

    Time frame: At Day 31

  27. CMI Response in Terms of Frequency of RSVPreF3-specific CD4 atl2_7m T Cells Expressing at Least 2 Activation Markers at Month 6

    Among markers expressed were IL2, IL13, IL17, CD40L, 41BB, TNF α and IFN γ, in vitro upon stimulation with RSVPreF3 peptide preparations.

    Time frame: At Month 6

  28. CMI Response in Terms of Frequency of RSVPreF3-specific CD8 atl2_7m T Cells Expressing at Least 2 Activation Markers at Month 6

    Among markers expressed were IL2, IL13, IL17, CD40L, 41BB, TNF α and IFN γ, in vitro upon stimulation with RSVPreF3 peptide preparations.

    Time frame: At Month 6

  29. CMI Response in Terms of Frequency of RSVPreF3-specific CD4 atl2_7m T Cells Expressing at Least 2 Activation Markers at Month 12

    Among markers expressed were IL2, IL13, IL17, CD40L, 41BB, TNF α and IFN γ, in vitro upon stimulation with RSVPreF3 peptide preparations.

    Time frame: At Month 12

  30. CMI Response in Terms of Frequency of RSVPreF3-specific CD8 atl2_7m T Cells Expressing at Least 2 Activation Markers at Month 12

    Among markers expressed were IL2, IL13, IL17, CD40L, 41BB, TNF α and IFN γ, in vitro upon stimulation with RSVPreF3 peptide preparations.

    Time frame: At Month 12

  31. CMI Response in Terms of Frequency of RSVPreF3-specific CD4 atl2_7m T Cells Expressing at Least 2 Activation Markers at Month 18

    Month 18 data will be disclosed during final posting. Among markers expressed were interleukin-2/13/17 (IL2, IL13, IL17), cluster of 40 ligand (CD40L), 41BB, tumor necrosis factor alpha (TNF α) and interferon gamma (IFN γ), in vitro upon stimulation with RSVPreF3 peptide preparations.

    Time frame: At Month 18

  32. CMI Response in Terms of Frequency of RSVPreF3-specific CD8 atl2_7m T Cells Expressing at Least 2 Activation Markers at Month 18

    Month 18 data will be disclosed during final posting. Among markers expressed were interleukin-2/13/17 (IL2, IL13, IL17), cluster of 40 ligand (CD40L), 41BB, tumor necrosis factor alpha (TNF α) and interferon gamma (IFN γ), in vitro upon stimulation with RSVPreF3 peptide preparations.

    Time frame: At Month 18

  33. CMI Response in Terms of Frequency of RSVPreF3-specific CD4 atl2_7m T Cells Expressing at Least 2 Activation Markers at Month 24

    Month 24 data will be disclosed during final posting. Among markers expressed were interleukin-2/13/17 (IL2, IL13, IL17), cluster of 40 ligand (CD40L), 41BB, tumor necrosis factor alpha (TNF α) and interferon gamma (IFN γ), in vitro upon stimulation with RSVPreF3 peptide preparations.

    Time frame: At Month 24

  34. CMI Response in Terms of Frequency of RSVPreF3-specific CD8 atl2_7m T Cells Expressing at Least 2 Activation Markers at Month 24

    Month 24 data will be disclosed during final posting. Among markers expressed were interleukin-2/13/17 (IL2, IL13, IL17), cluster of 40 ligand (CD40L), 41BB, tumor necrosis factor alpha (TNF α) and interferon gamma (IFN γ), in vitro upon stimulation with RSVPreF3 peptide preparations.

    Time frame: At Month 24

  35. CMI Response in Terms of Frequency of RSVPreF3-specific CD4 atl2_7m T Cells Expressing at Least 2 Activation Markers at Month 30

    Month 30 data will be disclosed during final posting. Among markers expressed were interleukin-2/13/17 (IL2, IL13, IL17), cluster of 40 ligand (CD40L), 41BB, tumor necrosis factor alpha (TNF α) and interferon gamma (IFN γ), in vitro upon stimulation with RSVPreF3 peptide preparations.

    Time frame: At Month 30

  36. CMI Response in Terms of Frequency of RSVPreF3-specific CD8 atl2_7m T Cells Expressing at Least 2 Activation Markers at Month 30

    Month 30 data will be disclosed during final posting. Among markers expressed were interleukin-2/13/17 (IL2, IL13, IL17), cluster of 40 ligand (CD40L), 41BB, tumor necrosis factor alpha (TNF α) and interferon gamma (IFN γ), in vitro upon stimulation with RSVPreF3 peptide preparations.

    Time frame: At Month 30

  37. CMI Response in Terms of Frequency of RSVPreF3-specific CD4 atl2_7m T Cells Expressing at Least 2 Activation Markers at Month 36

    Month 36 data will be disclosed during final posting. Among markers expressed were interleukin-2/13/17 (IL2, IL13, IL17), cluster of 40 ligand (CD40L), 41BB, tumor necrosis factor alpha (TNF α) and interferon gamma (IFN γ), in vitro upon stimulation with RSVPreF3 peptide preparations.

    Time frame: At Month 36

  38. CMI Response in Terms of Frequency of RSVPreF3-specific CD8 atl2_7m T Cells Expressing at Least 2 Activation Markers at Month 36

    Month 36 data will be disclosed during final posting. Among markers expressed were interleukin-2/13/17 (IL2, IL13, IL17), cluster of 40 ligand (CD40L), 41BB, tumor necrosis factor alpha (TNF α) and interferon gamma (IFN γ), in vitro upon stimulation with RSVPreF3 peptide preparations.

    Time frame: At Month 36

  39. CMI Response in Terms of Frequency of RSVPreF3-specific CD4 atl2_7m T Cells Expressing at Least 2 Activation Markers at Month 13

    Month 13 data will be disclosed during final posting. Among markers expressed were interleukin-2/13/17 (IL2, IL13, IL17), cluster of 40 ligand (CD40L), 41BB, tumor necrosis factor alpha (TNF α) and interferon gamma (IFN γ), in vitro upon stimulation with RSVPreF3 peptide preparations.

    Time frame: At Month 13

  40. CMI Response in Terms of Frequency of RSVPreF3-specific CD8 atl2_7m T Cells Expressing at Least 2 Activation Markers at Month 13

    Month 13 data will be disclosed during final posting. Among markers expressed were interleukin-2/13/17 (IL2, IL13, IL17), cluster of 40 ligand (CD40L), 41BB, tumor necrosis factor alpha (TNF α) and interferon gamma (IFN γ), in vitro upon stimulation with RSVPreF3 peptide preparations.

    Time frame: At Month 13

  41. CMI Response in Terms of Frequency of RSVPreF3-specific CD4 atl2_7m T Cells Expressing at Least 2 Activation Markers at Month 25

    Month 25 data will be disclosed during final posting. Among markers expressed were interleukin-2/13/17 (IL2, IL13, IL17), cluster of 40 ligand (CD40L), 41BB, tumor necrosis factor alpha (TNF α) and interferon gamma (IFN γ), in vitro upon stimulation with RSVPreF3 peptide preparations.

    Time frame: At Month 25

  42. CMI Response in Terms of Frequency of RSVPreF3-specific CD8 atl2_7m T Cells Expressing at Least 2 Activation Markers at Month 25

    Month 25 data will be disclosed during final posting. Among markers expressed were interleukin-2/13/17 (IL2, IL13, IL17), cluster of 40 ligand (CD40L), 41BB, tumor necrosis factor alpha (TNF α) and interferon gamma (IFN γ), in vitro upon stimulation with RSVPreF3 peptide preparations.

    Time frame: At Month 25

  43. Number of Participants With at Least One Solicited Administration-site Event Following Vaccination at Day 1

    The solicited administration-site events were erythema, pain and swelling at the injection site.

    Time frame: During the 4-day follow up period after first vaccination (vaccine administered on Day 1)

  44. Number of Participants With at Least One Solicited Administration-site Event Following Vaccination at Month 12

    Month 12 to Month 18 data will be disclosed during final posting. The solicited administration-site events were erythema, pain and swelling at the injection site.

    Time frame: During the 4-day follow up period after vaccination (vaccine administered at Month 12)

  45. Number of Participants With at Least One Solicited Administration-site Event Following Vaccination at Month 24

    Month 24 data will be disclosed during final posting. The solicited administration-site events were erythema, pain and swelling at the injection site.

    Time frame: During the 4-day follow up period after vaccination (vaccine administered at Month 24)

  46. Number of Participants With at Least One Solicited Systemic Event Following Vaccination at Day 1

    The solicited systemic events included arthralgia, fatigue, fever (defined as temperature equal to or above 38.0 degree Celsius \[°C\]), headache and myalgia.

    Time frame: During the 4-day follow up period after vaccination (vaccine administered on Day 1)

  47. Number of Participants With at Least One Solicited Systemic Event Following Vaccination at Month 12

    Month 12 to Month 18 data will be disclosed during final posting. The solicited systemic events included arthralgia, fatigue, fever (defined as temperature equal to or above 38.0°C), headache and myalgia.

    Time frame: During the 4-day follow up period after vaccination (vaccine administered at Month 12)

  48. Number of Participants With at Least One Solicited Systemic Event Following Vaccination at Month 24

    Month 24 data will be disclosed during final posting. The solicited systemic events included arthralgia, fatigue, fever (defined as temperature equal to or above 38.0 degree Celsius (°C)), headache and myalgia.

    Time frame: During the 4-day follow up period after vaccination (vaccine administered at Month 24)

  49. Number of Participants With Any Unsolicited Adverse Events (AEs) Following Vaccination at Day 1

    An unsolicited AE covers any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of study intervention, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study, and/or any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any is defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.

    Time frame: During the 30-day follow up period after vaccination (vaccine administered on Day 1)

  50. Number of Participants With Any Unsolicited AEs Following Vaccination at Month 12

    Month 12 to Month 18 data will be disclosed during final posting. An unsolicited AE covers any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of study intervention, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study, and/or any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any is defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.

    Time frame: During the 4-day follow up period after vaccination (vaccine administered at Month 12)

  51. Number of Participants With Any Unsolicited AEs Following Vaccination at Month 24

    Month 24 data will be disclosed during final posting. An unsolicited AE covers any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of study intervention, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study, and/or any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any is defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.

    Time frame: During the 4-day follow up period after vaccination (vaccine administered at Month 24)

  52. Number of Participants With Serious Adverse Events (SAE) Following Vaccination at Day 1

    An SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect in the offspring of a study participant.

    Time frame: From first vaccination (Day 1) up to 6 months post-Dose 1 (Month 6)

  53. Number of Participants With SAEs Following Vaccination at Month 12

    Month 12 to Month 18 data will be disclosed during final posting. An SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect in the offspring of a study participant.

    Time frame: During the 4-day follow up period after vaccination (vaccine administered at Month 12)

  54. Number of Participants With SAEs Following Vaccination at Month 24

    Month 24 data will be disclosed during final posting. An SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect in the offspring of a study participant.

    Time frame: During the 4-day follow up period after vaccination (vaccine administered at Month 24)

  55. Number of Participants Reporting Any Potential Immune-mediated Disease (pIMD) Following Vaccination at Day 1

    pIMDs are a subset of AEs of special interest that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune etiology.

    Time frame: From first vaccination (Day 1) up to 6 months post-Dose 1 (Month 6)

  56. Number of Participants Reporting Any pIMD Following Vaccination at Month 12

    Month 12 to Month 18 data will be disclosed during final posting. pIMDs are a subset of AEs of special interest that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune etiology.

    Time frame: During the 4-day follow up period after vaccination (vaccine administered at Month 12)

  57. Number of Participants Reporting Any pIMD Following Vaccination at Month 24

    Month 24 data will be disclosed during final posting. pIMDs are a subset of AEs of special interest that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune etiology.

    Time frame: During the 4-day follow up period after vaccination (vaccine administered at Month 24)

  58. Number of Participants With a Fatal SAE, Related SAE and Related pIMDs

    A fatal SAE is any untoward medical occurrence that results in death. A related SAE is an SAE considered to be causally related to the study intervention. A related pIMD is a pIMD considered to be causally related to the study intervention. The study is ongoing at the time of the results posting. Results for Months 18 up to study end (Month 36) will be updated during final posting.

    Time frame: From first vaccination (Day 1) up to study end (Month 36)

07

Results

Posted Dec 21, 2023

Participant flow

The demography, immunogenicity, reactogenicity and safety data currently presented is reported only for the first 12 months of the study timeline. The follow-up data (up to 36 months) will be updated during final posting.

Participant flow — Overall Study
MilestoneRSV_annualRSV_flexible RevaccinationRSV_1dose
Started993329331
Completed938317317
Not completed551214
Withdrew: Adverse event (ae) requiring expedited reporting913
Withdrew: Lost to follow-up743
Withdrew: Consent withdrawal, not due to a serious adverse event (sae)2676
Withdrew: Migrated / moved from the study area500
Withdrew: Other101
Withdrew: Ongoing601
Withdrew: Unsolicited non-serious adverse event100

Outcome measures

PrimaryHumoral Immune Response in Terms of Respiratory Syncytial Virus (RSV)-A Neutralizing Antibody Geometric Mean Titers (GMTs) at Day 1

RSV-A neutralizing antibodies were given as GMTs and expressed as Estimated Dose: serum dilution giving a 60% reduction of the RSV plaques compared to a control without serum (ED60).

Time frame:
At Day 1
Reported as:
Geometric mean · Titers (ED60)
Humoral Immune Response in Terms of Respiratory Syncytial Virus (RSV)-A Neutralizing Antibody Geometric Mean Titers (GMTs) at Day 1
Titers (ED60)RSV_annualRSV_flexible RevaccinationRSV_1dose
Humoral Immune Response in Terms of Respiratory Syncytial Virus (RSV)-A Neutralizing Antibody Geometric Mean Titers (GMTs) at Day 1832.4 (763.4 to 907.7)864.9 (790.6 to 946.1)896.8 (815.9 to 985.8)
PrimaryHumoral Immune Response in Terms of RSV-A Neutralizing Antibody GMTs at Day 31

RSV-A neutralizing antibodies were given as GMTs and expressed as ED60.

Time frame:
At Day 31
Reported as:
Geometric mean · Titers (ED60)
Humoral Immune Response in Terms of RSV-A Neutralizing Antibody GMTs at Day 31
Titers (ED60)RSV_annualRSV_flexible RevaccinationRSV_1dose
Humoral Immune Response in Terms of RSV-A Neutralizing Antibody GMTs at Day 318827.2 (7905 to 9857)8906.6 (7972.3 to 9950.3)9585.6 (8448.8 to 10875.5)
PrimaryHumoral Immune Response in Terms of RSV-A Neutralizing Antibody GMTs at Month 6

RSV-A neutralizing antibodies were given as GMTs and expressed as ED60.

Time frame:
At Month 6
Reported as:
Geometric mean · Titers (ED60)
Humoral Immune Response in Terms of RSV-A Neutralizing Antibody GMTs at Month 6
Titers (ED60)RSV_annualRSV_flexible RevaccinationRSV_1dose
Humoral Immune Response in Terms of RSV-A Neutralizing Antibody GMTs at Month 63465.2 (3140.9 to 3823)3600.1 (3242.2 to 3997.5)4223.1 (3795.3 to 4699)
PrimaryHumoral Immune Response in Terms of RSV-A Neutralizing Antibody GMTs at Month 12

RSV-A neutralizing antibodies were given as GMTs and expressed as ED60.

Time frame:
At Month 12
Reported as:
Geometric mean · Titers (ED60)
Humoral Immune Response in Terms of RSV-A Neutralizing Antibody GMTs at Month 12
Titers (ED60)RSV_annualRSV_flexible RevaccinationRSV_1dose
Humoral Immune Response in Terms of RSV-A Neutralizing Antibody GMTs at Month 122529.9 (2274.5 to 2814)2695.7 (2421.4 to 3001)2800.1 (2501.6 to 3134.3)
PrimaryHumoral Immune Response in Terms of RSV-B Neutralizing Antibody Titers at Day 1

RSV-B neutralizing antibodies measured as GMTs and expressed as ED60.

Time frame:
At Day 1
Reported as:
Geometric mean · Titers (ED60)
Humoral Immune Response in Terms of RSV-B Neutralizing Antibody Titers at Day 1
Titers (ED60)RSV_annualRSV_flexible RevaccinationRSV_1dose
Humoral Immune Response in Terms of RSV-B Neutralizing Antibody Titers at Day 11138.7 (1046.2 to 1239.3)1325.9 (1206.9 to 1456.6)1258.7 (1142 to 1387.4)
PrimaryHumoral Immune Response in Terms of RSV-B Neutralizing Antibody Titers at Day 31

RSV-B neutralizing antibodies measured as GMTs and expressed as ED60.

Time frame:
At Day 31
Reported as:
Geometric mean · Titers (ED60)
Humoral Immune Response in Terms of RSV-B Neutralizing Antibody Titers at Day 31
Titers (ED60)RSV_annualRSV_flexible RevaccinationRSV_1dose
Humoral Immune Response in Terms of RSV-B Neutralizing Antibody Titers at Day 319219.7 (8368.7 to 10157.3)9955.2 (9002.1 to 11009.3)9756.1 (8785.4 to 10834)
PrimaryHumoral Immune Response in Terms of RSV-B Neutralizing Antibody Titers at Month 6

RSV-B neutralizing antibodies measured as GMTs and expressed as ED60.

Time frame:
At Month 6
Reported as:
Geometric mean · Titers (ED60)
Humoral Immune Response in Terms of RSV-B Neutralizing Antibody Titers at Month 6
Titers (ED60)RSV_annualRSV_flexible RevaccinationRSV_1dose
Humoral Immune Response in Terms of RSV-B Neutralizing Antibody Titers at Month 63886.4 (3563.5 to 4238.6)4484.6 (4063.8 to 4949)4570.6 (4152 to 5031.4)
PrimaryHumoral Immune Response in Terms of RSV-B Neutralizing Antibody Titers at Month 12

RSV-B neutralizing antibodies measured as GMTs and expressed as ED60.

Time frame:
At Month 12
Reported as:
Geometric mean · Titers (ED60)
Humoral Immune Response in Terms of RSV-B Neutralizing Antibody Titers at Month 12
Titers (ED60)RSV_annualRSV_flexible RevaccinationRSV_1dose
Humoral Immune Response in Terms of RSV-B Neutralizing Antibody Titers at Month 122671.4 (2433.3 to 2932.9)3015.4 (2737.9 to 3321)2977.1 (2669.6 to 3320)
SecondaryHumoral Immune Response in Terms of RSVPreF3 Immunoglobulin G (IgG) Antibody Geometric Mean Concentrations (GMCs) at Day 1

Serological assays for the determination of IgG antibodies against RSV PreF3 are performed by enzyme-linked immunosorbent assay (ELISA). The corresponding antibody GMC was expressed in Elisa Laboratory Units/milliliter (ELU/mL).

Time frame:
At Day 1
Reported as:
Geometric mean · ELU/mL
Humoral Immune Response in Terms of RSVPreF3 Immunoglobulin G (IgG) Antibody Geometric Mean Concentrations (GMCs) at Day 1
ELU/mLRSV_annualRSV_flexible RevaccinationRSV_1dose
Humoral Immune Response in Terms of RSVPreF3 Immunoglobulin G (IgG) Antibody Geometric Mean Concentrations (GMCs) at Day 17334.7 (6868.3 to 7832.8)7437.1 (6948.6 to 7959.9)7759 (7212.5 to 8346.8)
SecondaryHumoral Immune Response in Terms of RSVPreF3 IgG Antibody GMCs at Day 31

Serological assays for the determination of IgG antibodies against RSV PreF3 are performed by ELISA. The corresponding antibody GMC was expressed in ELU/mL.

Time frame:
At Day 31
Reported as:
Geometric mean · ELU/mL
Humoral Immune Response in Terms of RSVPreF3 IgG Antibody GMCs at Day 31
ELU/mLRSV_annualRSV_flexible RevaccinationRSV_1dose
Humoral Immune Response in Terms of RSVPreF3 IgG Antibody GMCs at Day 3186929.7 (80662.7 to 93683.6)92664.7 (86050.1 to 99787.8)94249.4 (87660.7 to 101333.3)
SecondaryHumoral Immune Response in Terms of RSVPreF3 IgG Antibody GMCs at Month 6

Serological assays for the determination of IgG antibodies against RSV PreF3 are performed by ELISA. The corresponding antibody GMC was expressed in ELU/mL.

Time frame:
At Month 6
Reported as:
Geometric mean · ELU/mL
Humoral Immune Response in Terms of RSVPreF3 IgG Antibody GMCs at Month 6
ELU/mLRSV_annualRSV_flexible RevaccinationRSV_1dose
Humoral Immune Response in Terms of RSVPreF3 IgG Antibody GMCs at Month 633855.9 (31405.3 to 36497.7)35193.5 (32623.6 to 37965.9)36525.7 (33938 to 39310.7)
SecondaryHumoral Immune Response in Terms of RSVPreF3 IgG Antibody GMCs at Month 12

Serological assays for the determination of IgG antibodies against RSV PreF3 are performed by ELISA. The corresponding antibody GMC was expressed in ELU/mL.

Time frame:
At Month 12
Reported as:
Geometric mean · ELU/mL
Humoral Immune Response in Terms of RSVPreF3 IgG Antibody GMCs at Month 12
ELU/mLRSV_annualRSV_flexible RevaccinationRSV_1dose
Humoral Immune Response in Terms of RSVPreF3 IgG Antibody GMCs at Month 1224733.5 (22994.3 to 26604.2)26484.1 (24651.7 to 28452.8)27360.3 (25476.7 to 29383)
SecondaryHumoral Immune Response in Terms of RSV-A Neutralizing Antibody GMTs at Month 18

Month 18 data will be disclosed during final posting. RSV-A neutralizing antibodies were given as GMTs and expressed as Estimated Dose: serum dilution giving a 60% reduction of the RSV plaques compared to a control without serum (ED60).

Time frame:
At Month 18

Results for this outcome have not been posted.

SecondaryHumoral Immune Response in Terms of RSV-A Neutralizing Antibody GMTs at Month 24

Month 24 data will be disclosed during final posting. RSV-A neutralizing antibodies were given as GMTs and expressed as Estimated Dose: serum dilution giving a 60% reduction of the RSV plaques compared to a control without serum (ED60).

Time frame:
At Month 24

Results for this outcome have not been posted.

SecondaryHumoral Immune Response in Terms of RSV-A Neutralizing Antibody GMTs at Month 30

Month 30 data will be disclosed during final posting. RSV-A neutralizing antibodies were given as GMTs and expressed as Estimated Dose: serum dilution giving a 60% reduction of the RSV plaques compared to a control without serum (ED60).

Time frame:
At Month 30

Results for this outcome have not been posted.

SecondaryHumoral Immune Response in Terms of RSV-A Neutralizing Antibody GMTs at Month 36

Month 36 data will be disclosed during final posting. RSV-A neutralizing antibodies were given as GMTs and expressed as Estimated Dose: serum dilution giving a 60% reduction of the RSV plaques compared to a control without serum (ED60).

Time frame:
At Month 36

Results for this outcome have not been posted.

SecondaryHumoral Immune Response in Terms of RSV-A Neutralizing Antibody GMTs at Month 13

Month 13 data will be disclosed during final posting. RSV-A neutralizing antibodies were given as GMTs and expressed as Estimated Dose: serum dilution giving a 60% reduction of the RSV plaques compared to a control without serum (ED60).

Time frame:
At Month 13

Results for this outcome have not been posted.

SecondaryHumoral Immune Response in Terms of RSV-A Neutralizing Antibody GMTs at Month 25

Month 25 data will be disclosed during final posting. RSV-A neutralizing antibodies were given as GMTs and expressed as Estimated Dose: serum dilution giving a 60% reduction of the RSV plaques compared to a control without serum (ED60).

Time frame:
At Month 25

Results for this outcome have not been posted.

SecondaryHumoral Immune Response in Terms of RSV-B Neutralizing Antibody Titers at Month 18

Month 18 data will be disclosed during final posting. RSV-B neutralizing antibodies were given as GMTs and expressed as Estimated Dose: serum dilution giving a 60% reduction of the RSV plaques compared to a control without serum (ED60).

Time frame:
At Month 18

Results for this outcome have not been posted.

SecondaryHumoral Immune Response in Terms of RSV-B Neutralizing Antibody Titers at Month 24

Month 24 data will be disclosed during final posting. RSV-B neutralizing antibodies were given as GMTs and expressed as Estimated Dose: serum dilution giving a 60% reduction of the RSV plaques compared to a control without serum (ED60).

Time frame:
At Month 24

Results for this outcome have not been posted.

SecondaryHumoral Immune Response in Terms of RSV-B Neutralizing Antibody Titers at Month 30

Month 30 data will be disclosed during final posting. RSV-B neutralizing antibodies were given as GMTs and expressed as Estimated Dose: serum dilution giving a 60% reduction of the RSV plaques compared to a control without serum (ED60).

Time frame:
At Month 30

Results for this outcome have not been posted.

SecondaryHumoral Immune Response in Terms of RSV-B Neutralizing Antibody Titers at Month 36

Month 36 data will be disclosed during final posting. RSV-B neutralizing antibodies were given as GMTs and expressed as Estimated Dose: serum dilution giving a 60% reduction of the RSV plaques compared to a control without serum (ED60).

Time frame:
At Month 36

Results for this outcome have not been posted.

SecondaryHumoral Immune Response in Terms of RSV-B Neutralizing Antibody Titers at Month 13

Month 13 data will be disclosed during final posting. RSV-B neutralizing antibodies were given as GMTs and expressed as Estimated Dose: serum dilution giving a 60% reduction of the RSV plaques compared to a control without serum (ED60).

Time frame:
At Month 13

Results for this outcome have not been posted.

SecondaryHumoral Immune Response in Terms of RSV-B Neutralizing Antibody Titers at Month 25

Month 25 data will be disclosed during final posting. RSV-B neutralizing antibodies were given as GMTs and expressed as Estimated Dose: serum dilution giving a 60% reduction of the RSV plaques compared to a control without serum (ED60).

Time frame:
At Month 25

Results for this outcome have not been posted.

SecondaryHumoral Immune Response in Terms of RSVPreF3 IgG Antibody GMCs at Month 18

Month 18 data will be disclosed during final posting. Serological assays for the determination of IgG antibodies against RSV PreF3 were performed by ELISA. The corresponding antibody GMC was expressed in ELU/mL.

Time frame:
At Month 18

Results for this outcome have not been posted.

SecondaryHumoral Immune Response in Terms of RSVPreF3 IgG Antibody GMCs at Month 24

Month 24 data will be disclosed during final posting. Serological assays for the determination of IgG antibodies against RSV PreF3 were performed by ELISA. The corresponding antibody GMC was expressed in ELU/mL.

Time frame:
At Month 24

Results for this outcome have not been posted.

SecondaryHumoral Immune Response in Terms of RSVPreF3 IgG Antibody GMCs at Month 30

Month 30 data will be disclosed during final posting. Serological assays for the determination of IgG antibodies against RSV PreF3 were performed by ELISA. The corresponding antibody GMC was expressed in ELU/mL.

Time frame:
At Month 30

Results for this outcome have not been posted.

SecondaryHumoral Immune Response in Terms of RSVPreF3 IgG Antibody GMCs at Month 36

Month 36 data will be disclosed during final posting. Serological assays for the determination of IgG antibodies against RSV PreF3 were performed by ELISA. The corresponding antibody GMC was expressed in ELU/mL.

Time frame:
At Month 36

Results for this outcome have not been posted.

SecondaryHumoral Immune Response in Terms of RSVPreF3 IgG Antibody GMCs at Month 13

Month 13 data will be disclosed during final posting. Serological assays for the determination of IgG antibodies against RSV PreF3 were performed by ELISA. The corresponding antibody GMC was expressed in ELU/mL.

Time frame:
At Month 13

Results for this outcome have not been posted.

SecondaryHumoral Immune Response in Terms of RSVPreF3 IgG Antibody GMCs at Month 25

Month 25 data will be disclosed during final posting. Serological assays for the determination of IgG antibodies against RSV PreF3 were performed by ELISA. The corresponding antibody GMC was expressed in ELU/mL.

Time frame:
At Month 25

Results for this outcome have not been posted.

SecondaryCell-Mediated Immunity (CMI) Response in Terms of Frequency of RSVPreF3-specific Cluster of Differentiation CD4 atl2_7m T Cells Expressing at Least 2 Activation Markers at Day 1

Among markers expressed were interleukin-2/13/17 (IL2, IL13, IL17), cluster of 40 ligand (CD40L), 41BB, tumor necrosis factor alpha (TNF α) and interferon gamma (IFN γ), in vitro upon stimulation with RSVPreF3 peptide preparations.

Time frame:
At Day 1
Reported as:
Median · CD4 atl2_7m/ million of CD4+ cells
Cell-Mediated Immunity (CMI) Response in Terms of Frequency of RSVPreF3-specific Cluster of Differentiation CD4 atl2_7m T Cells Expressing at Least 2 Activation Markers at Day 1
CD4 atl2_7m/ million of CD4+ cellsRSV_annualRSV_flexible RevaccinationRSV_1dose
Cell-Mediated Immunity (CMI) Response in Terms of Frequency of RSVPreF3-specific Cluster of Differentiation CD4 atl2_7m T Cells Expressing at Least 2 Activation Markers at Day 1202 (83 to 376)143 (26 to 294)171 (65 to 385)
SecondaryCMI Response in Terms of Frequency of RSVPreF3-specific CD8 atl2_7m T Cells Expressing at Least 2 Activation Markers at Day 1

Among markers expressed were IL2, IL13, IL17, CD40L, 41BB, TNF α and IFN γ, in vitro upon stimulation with RSVPreF3 peptide preparations.

Time frame:
At Day 1
Reported as:
Median · CD8 atl2_7m/ million of CD8+ cells
CMI Response in Terms of Frequency of RSVPreF3-specific CD8 atl2_7m T Cells Expressing at Least 2 Activation Markers at Day 1
CD8 atl2_7m/ million of CD8+ cellsRSV_annualRSV_flexible RevaccinationRSV_1dose
CMI Response in Terms of Frequency of RSVPreF3-specific CD8 atl2_7m T Cells Expressing at Least 2 Activation Markers at Day 133 (1 to 110)32 (1 to 103)2 (1 to 107)
SecondaryCMI Response in Terms of Frequency of RSVPreF3-specific CD4 atl2_7m T Cells Expressing at Least 2 Activation Markers at Day 31

Among markers expressed were IL2, IL13, IL17, CD40L, 41BB, TNF α and IFN γ, in vitro upon stimulation with RSVPreF3 peptide preparations.

Time frame:
At Day 31
Reported as:
Median · CD4 atl2_7m/ million of CD4+ cells
CMI Response in Terms of Frequency of RSVPreF3-specific CD4 atl2_7m T Cells Expressing at Least 2 Activation Markers at Day 31
CD4 atl2_7m/ million of CD4+ cellsRSV_annualRSV_flexible RevaccinationRSV_1dose
CMI Response in Terms of Frequency of RSVPreF3-specific CD4 atl2_7m T Cells Expressing at Least 2 Activation Markers at Day 311310 (813 to 2155)1292.5 (820.5 to 2254)1570 (876 to 1971)
SecondaryCMI Response in Terms of Frequency of RSVPreF3-specific CD8 atl2_7m T Cells Expressing at Least 2 Activation Markers at Day 31

Among markers expressed were IL2, IL13, IL17, CD40L, 41BB, TNF α and IFN γ, in vitro upon stimulation with RSVPreF3 peptide preparations.

Time frame:
At Day 31
Reported as:
Median · CD8 atl2_7m/ million of CD8+ cells
CMI Response in Terms of Frequency of RSVPreF3-specific CD8 atl2_7m T Cells Expressing at Least 2 Activation Markers at Day 31
CD8 atl2_7m/ million of CD8+ cellsRSV_annualRSV_flexible RevaccinationRSV_1dose
CMI Response in Terms of Frequency of RSVPreF3-specific CD8 atl2_7m T Cells Expressing at Least 2 Activation Markers at Day 3126 (1 to 129)58 (1 to 143)5 (1 to 101)
SecondaryCMI Response in Terms of Frequency of RSVPreF3-specific CD4 atl2_7m T Cells Expressing at Least 2 Activation Markers at Month 6

Among markers expressed were IL2, IL13, IL17, CD40L, 41BB, TNF α and IFN γ, in vitro upon stimulation with RSVPreF3 peptide preparations.

Time frame:
At Month 6
Reported as:
Median · CD4 atl2_7m/ million of CD4+ cells
CMI Response in Terms of Frequency of RSVPreF3-specific CD4 atl2_7m T Cells Expressing at Least 2 Activation Markers at Month 6
CD4 atl2_7m/ million of CD4+ cellsRSV_annualRSV_flexible RevaccinationRSV_1dose
CMI Response in Terms of Frequency of RSVPreF3-specific CD4 atl2_7m T Cells Expressing at Least 2 Activation Markers at Month 6662 (428 to 1026)644 (442 to 1100)695 (427 to 1131)
SecondaryCMI Response in Terms of Frequency of RSVPreF3-specific CD8 atl2_7m T Cells Expressing at Least 2 Activation Markers at Month 6

Among markers expressed were IL2, IL13, IL17, CD40L, 41BB, TNF α and IFN γ, in vitro upon stimulation with RSVPreF3 peptide preparations.

Time frame:
At Month 6
Reported as:
Median · CD8 atl2_7m/ million of CD8+ cells
CMI Response in Terms of Frequency of RSVPreF3-specific CD8 atl2_7m T Cells Expressing at Least 2 Activation Markers at Month 6
CD8 atl2_7m/ million of CD8+ cellsRSV_annualRSV_flexible RevaccinationRSV_1dose
CMI Response in Terms of Frequency of RSVPreF3-specific CD8 atl2_7m T Cells Expressing at Least 2 Activation Markers at Month 638 (1 to 113)24.5 (1 to 103.5)26 (1 to 87)
SecondaryCMI Response in Terms of Frequency of RSVPreF3-specific CD4 atl2_7m T Cells Expressing at Least 2 Activation Markers at Month 12

Among markers expressed were IL2, IL13, IL17, CD40L, 41BB, TNF α and IFN γ, in vitro upon stimulation with RSVPreF3 peptide preparations.

Time frame:
At Month 12
Reported as:
Median · CD4 atl2_7m/ million of CD4+ cells
CMI Response in Terms of Frequency of RSVPreF3-specific CD4 atl2_7m T Cells Expressing at Least 2 Activation Markers at Month 12
CD4 atl2_7m/ million of CD4+ cellsRSV_annualRSV_flexible RevaccinationRSV_1dose
CMI Response in Terms of Frequency of RSVPreF3-specific CD4 atl2_7m T Cells Expressing at Least 2 Activation Markers at Month 12564 (348 to 898)525 (345 to 818)671 (374.5 to 1072.5)
SecondaryCMI Response in Terms of Frequency of RSVPreF3-specific CD8 atl2_7m T Cells Expressing at Least 2 Activation Markers at Month 12

Among markers expressed were IL2, IL13, IL17, CD40L, 41BB, TNF α and IFN γ, in vitro upon stimulation with RSVPreF3 peptide preparations.

Time frame:
At Month 12
Reported as:
Median · CD8 atl2_7m/ million of CD8+ cells
CMI Response in Terms of Frequency of RSVPreF3-specific CD8 atl2_7m T Cells Expressing at Least 2 Activation Markers at Month 12
CD8 atl2_7m/ million of CD8+ cellsRSV_annualRSV_flexible RevaccinationRSV_1dose
CMI Response in Terms of Frequency of RSVPreF3-specific CD8 atl2_7m T Cells Expressing at Least 2 Activation Markers at Month 121 (1 to 81)18 (1 to 108)22 (1 to 104)
SecondaryCMI Response in Terms of Frequency of RSVPreF3-specific CD4 atl2_7m T Cells Expressing at Least 2 Activation Markers at Month 18

Month 18 data will be disclosed during final posting. Among markers expressed were interleukin-2/13/17 (IL2, IL13, IL17), cluster of 40 ligand (CD40L), 41BB, tumor necrosis factor alpha (TNF α) and interferon gamma (IFN γ), in vitro upon stimulation with RSVPreF3 peptide preparations.

Time frame:
At Month 18

Results for this outcome have not been posted.

SecondaryCMI Response in Terms of Frequency of RSVPreF3-specific CD8 atl2_7m T Cells Expressing at Least 2 Activation Markers at Month 18

Month 18 data will be disclosed during final posting. Among markers expressed were interleukin-2/13/17 (IL2, IL13, IL17), cluster of 40 ligand (CD40L), 41BB, tumor necrosis factor alpha (TNF α) and interferon gamma (IFN γ), in vitro upon stimulation with RSVPreF3 peptide preparations.

Time frame:
At Month 18

Results for this outcome have not been posted.

SecondaryCMI Response in Terms of Frequency of RSVPreF3-specific CD4 atl2_7m T Cells Expressing at Least 2 Activation Markers at Month 24

Month 24 data will be disclosed during final posting. Among markers expressed were interleukin-2/13/17 (IL2, IL13, IL17), cluster of 40 ligand (CD40L), 41BB, tumor necrosis factor alpha (TNF α) and interferon gamma (IFN γ), in vitro upon stimulation with RSVPreF3 peptide preparations.

Time frame:
At Month 24

Results for this outcome have not been posted.

SecondaryCMI Response in Terms of Frequency of RSVPreF3-specific CD8 atl2_7m T Cells Expressing at Least 2 Activation Markers at Month 24

Month 24 data will be disclosed during final posting. Among markers expressed were interleukin-2/13/17 (IL2, IL13, IL17), cluster of 40 ligand (CD40L), 41BB, tumor necrosis factor alpha (TNF α) and interferon gamma (IFN γ), in vitro upon stimulation with RSVPreF3 peptide preparations.

Time frame:
At Month 24

Results for this outcome have not been posted.

SecondaryCMI Response in Terms of Frequency of RSVPreF3-specific CD4 atl2_7m T Cells Expressing at Least 2 Activation Markers at Month 30

Month 30 data will be disclosed during final posting. Among markers expressed were interleukin-2/13/17 (IL2, IL13, IL17), cluster of 40 ligand (CD40L), 41BB, tumor necrosis factor alpha (TNF α) and interferon gamma (IFN γ), in vitro upon stimulation with RSVPreF3 peptide preparations.

Time frame:
At Month 30

Results for this outcome have not been posted.

SecondaryCMI Response in Terms of Frequency of RSVPreF3-specific CD8 atl2_7m T Cells Expressing at Least 2 Activation Markers at Month 30

Month 30 data will be disclosed during final posting. Among markers expressed were interleukin-2/13/17 (IL2, IL13, IL17), cluster of 40 ligand (CD40L), 41BB, tumor necrosis factor alpha (TNF α) and interferon gamma (IFN γ), in vitro upon stimulation with RSVPreF3 peptide preparations.

Time frame:
At Month 30

Results for this outcome have not been posted.

SecondaryCMI Response in Terms of Frequency of RSVPreF3-specific CD4 atl2_7m T Cells Expressing at Least 2 Activation Markers at Month 36

Month 36 data will be disclosed during final posting. Among markers expressed were interleukin-2/13/17 (IL2, IL13, IL17), cluster of 40 ligand (CD40L), 41BB, tumor necrosis factor alpha (TNF α) and interferon gamma (IFN γ), in vitro upon stimulation with RSVPreF3 peptide preparations.

Time frame:
At Month 36

Results for this outcome have not been posted.

SecondaryCMI Response in Terms of Frequency of RSVPreF3-specific CD8 atl2_7m T Cells Expressing at Least 2 Activation Markers at Month 36

Month 36 data will be disclosed during final posting. Among markers expressed were interleukin-2/13/17 (IL2, IL13, IL17), cluster of 40 ligand (CD40L), 41BB, tumor necrosis factor alpha (TNF α) and interferon gamma (IFN γ), in vitro upon stimulation with RSVPreF3 peptide preparations.

Time frame:
At Month 36

Results for this outcome have not been posted.

SecondaryCMI Response in Terms of Frequency of RSVPreF3-specific CD4 atl2_7m T Cells Expressing at Least 2 Activation Markers at Month 13

Month 13 data will be disclosed during final posting. Among markers expressed were interleukin-2/13/17 (IL2, IL13, IL17), cluster of 40 ligand (CD40L), 41BB, tumor necrosis factor alpha (TNF α) and interferon gamma (IFN γ), in vitro upon stimulation with RSVPreF3 peptide preparations.

Time frame:
At Month 13

Results for this outcome have not been posted.

SecondaryCMI Response in Terms of Frequency of RSVPreF3-specific CD8 atl2_7m T Cells Expressing at Least 2 Activation Markers at Month 13

Month 13 data will be disclosed during final posting. Among markers expressed were interleukin-2/13/17 (IL2, IL13, IL17), cluster of 40 ligand (CD40L), 41BB, tumor necrosis factor alpha (TNF α) and interferon gamma (IFN γ), in vitro upon stimulation with RSVPreF3 peptide preparations.

Time frame:
At Month 13

Results for this outcome have not been posted.

SecondaryCMI Response in Terms of Frequency of RSVPreF3-specific CD4 atl2_7m T Cells Expressing at Least 2 Activation Markers at Month 25

Month 25 data will be disclosed during final posting. Among markers expressed were interleukin-2/13/17 (IL2, IL13, IL17), cluster of 40 ligand (CD40L), 41BB, tumor necrosis factor alpha (TNF α) and interferon gamma (IFN γ), in vitro upon stimulation with RSVPreF3 peptide preparations.

Time frame:
At Month 25

Results for this outcome have not been posted.

SecondaryCMI Response in Terms of Frequency of RSVPreF3-specific CD8 atl2_7m T Cells Expressing at Least 2 Activation Markers at Month 25

Month 25 data will be disclosed during final posting. Among markers expressed were interleukin-2/13/17 (IL2, IL13, IL17), cluster of 40 ligand (CD40L), 41BB, tumor necrosis factor alpha (TNF α) and interferon gamma (IFN γ), in vitro upon stimulation with RSVPreF3 peptide preparations.

Time frame:
At Month 25

Results for this outcome have not been posted.

SecondaryNumber of Participants With at Least One Solicited Administration-site Event Following Vaccination at Day 1

The solicited administration-site events were erythema, pain and swelling at the injection site.

Time frame:
During the 4-day follow up period after first vaccination (vaccine administered on Day 1)
Reported as:
Count of participants · Participants
Number of Participants With at Least One Solicited Administration-site Event Following Vaccination at Day 1
ParticipantsRSV_annualRSV_flexible RevaccinationRSV_1dose
Erythema993822
Pain595201200
Swelling753316
SecondaryNumber of Participants With at Least One Solicited Administration-site Event Following Vaccination at Month 12

Month 12 to Month 18 data will be disclosed during final posting. The solicited administration-site events were erythema, pain and swelling at the injection site.

Time frame:
During the 4-day follow up period after vaccination (vaccine administered at Month 12)

Results for this outcome have not been posted.

SecondaryNumber of Participants With at Least One Solicited Administration-site Event Following Vaccination at Month 24

Month 24 data will be disclosed during final posting. The solicited administration-site events were erythema, pain and swelling at the injection site.

Time frame:
During the 4-day follow up period after vaccination (vaccine administered at Month 24)

Results for this outcome have not been posted.

SecondaryNumber of Participants With at Least One Solicited Systemic Event Following Vaccination at Day 1

The solicited systemic events included arthralgia, fatigue, fever (defined as temperature equal to or above 38.0 degree Celsius \[°C\]), headache and myalgia.

Time frame:
During the 4-day follow up period after vaccination (vaccine administered on Day 1)
Reported as:
Count of participants · Participants
Number of Participants With at Least One Solicited Systemic Event Following Vaccination at Day 1
ParticipantsRSV_annualRSV_flexible RevaccinationRSV_1dose
Arthralgia1574949
Fatigue307100110
Fever1357
Headache1877079
Myalgia336107109
SecondaryNumber of Participants With at Least One Solicited Systemic Event Following Vaccination at Month 12

Month 12 to Month 18 data will be disclosed during final posting. The solicited systemic events included arthralgia, fatigue, fever (defined as temperature equal to or above 38.0°C), headache and myalgia.

Time frame:
During the 4-day follow up period after vaccination (vaccine administered at Month 12)

Results for this outcome have not been posted.

SecondaryNumber of Participants With at Least One Solicited Systemic Event Following Vaccination at Month 24

Month 24 data will be disclosed during final posting. The solicited systemic events included arthralgia, fatigue, fever (defined as temperature equal to or above 38.0 degree Celsius (°C)), headache and myalgia.

Time frame:
During the 4-day follow up period after vaccination (vaccine administered at Month 24)

Results for this outcome have not been posted.

SecondaryNumber of Participants With Any Unsolicited Adverse Events (AEs) Following Vaccination at Day 1

An unsolicited AE covers any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of study intervention, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study, and/or any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any is defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.

Time frame:
During the 30-day follow up period after vaccination (vaccine administered on Day 1)
Reported as:
Count of participants · Participants
Number of Participants With Any Unsolicited Adverse Events (AEs) Following Vaccination at Day 1
ParticipantsRSV_annualRSV_flexible RevaccinationRSV_1dose
Number of Participants With Any Unsolicited Adverse Events (AEs) Following Vaccination at Day 11254555
SecondaryNumber of Participants With Any Unsolicited AEs Following Vaccination at Month 12

Month 12 to Month 18 data will be disclosed during final posting. An unsolicited AE covers any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of study intervention, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study, and/or any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any is defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.

Time frame:
During the 4-day follow up period after vaccination (vaccine administered at Month 12)

Results for this outcome have not been posted.

SecondaryNumber of Participants With Any Unsolicited AEs Following Vaccination at Month 24

Month 24 data will be disclosed during final posting. An unsolicited AE covers any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of study intervention, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study, and/or any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any is defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.

Time frame:
During the 4-day follow up period after vaccination (vaccine administered at Month 24)

Results for this outcome have not been posted.

SecondaryNumber of Participants With Serious Adverse Events (SAE) Following Vaccination at Day 1

An SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect in the offspring of a study participant.

Time frame:
From first vaccination (Day 1) up to 6 months post-Dose 1 (Month 6)
Reported as:
Count of participants · Participants
Number of Participants With Serious Adverse Events (SAE) Following Vaccination at Day 1
ParticipantsRSV_annualRSV_flexible RevaccinationRSV_1dose
Number of Participants With Serious Adverse Events (SAE) Following Vaccination at Day 1361615
SecondaryNumber of Participants With SAEs Following Vaccination at Month 12

Month 12 to Month 18 data will be disclosed during final posting. An SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect in the offspring of a study participant.

Time frame:
During the 4-day follow up period after vaccination (vaccine administered at Month 12)

Results for this outcome have not been posted.

SecondaryNumber of Participants With SAEs Following Vaccination at Month 24

Month 24 data will be disclosed during final posting. An SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect in the offspring of a study participant.

Time frame:
During the 4-day follow up period after vaccination (vaccine administered at Month 24)

Results for this outcome have not been posted.

SecondaryNumber of Participants Reporting Any Potential Immune-mediated Disease (pIMD) Following Vaccination at Day 1

pIMDs are a subset of AEs of special interest that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune etiology.

Time frame:
From first vaccination (Day 1) up to 6 months post-Dose 1 (Month 6)
Reported as:
Count of participants · Participants
Number of Participants Reporting Any Potential Immune-mediated Disease (pIMD) Following Vaccination at Day 1
ParticipantsRSV_annualRSV_flexible RevaccinationRSV_1dose
Number of Participants Reporting Any Potential Immune-mediated Disease (pIMD) Following Vaccination at Day 1010
SecondaryNumber of Participants Reporting Any pIMD Following Vaccination at Month 12

Month 12 to Month 18 data will be disclosed during final posting. pIMDs are a subset of AEs of special interest that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune etiology.

Time frame:
During the 4-day follow up period after vaccination (vaccine administered at Month 12)

Results for this outcome have not been posted.

SecondaryNumber of Participants Reporting Any pIMD Following Vaccination at Month 24

Month 24 data will be disclosed during final posting. pIMDs are a subset of AEs of special interest that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune etiology.

Time frame:
During the 4-day follow up period after vaccination (vaccine administered at Month 24)

Results for this outcome have not been posted.

SecondaryNumber of Participants With a Fatal SAE, Related SAE and Related pIMDs

A fatal SAE is any untoward medical occurrence that results in death. A related SAE is an SAE considered to be causally related to the study intervention. A related pIMD is a pIMD considered to be causally related to the study intervention. The study is ongoing at the time of the results posting. Results for Months 18 up to study end (Month 36) will be updated during final posting.

Time frame:
From first vaccination (Day 1) up to study end (Month 36)

Results for this outcome have not been posted.

Adverse events

Collected over Serious Adverse Events (SAEs) were collected from Day 1 to Month 12. Non-serious adverse (Other Adverse events) events were collected within 30 days following first vaccination (vaccine administered at Day 1). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
RSV_annual3/993 (0.3%)46/993 (4.6%)744/993 (74.9%)
RSV_flexible Revaccination1/329 (0.3%)16/329 (4.9%)251/329 (76.3%)
RSV_1dose3/331 (0.9%)19/331 (5.7%)253/331 (76.4%)
Most frequent serious events
Showing 10 of 84
Most frequent serious events
EventRSV_annualRSV_flexible RevaccinationRSV_1dose
DeathGeneral disorders7/9934/3295/331
Atrial fibrillationCardiac disorders2/9932/3292/331
Coronary artery diseaseCardiac disorders3/9931/3290/331
Myocardial infarctionCardiac disorders1/9931/3290/331
Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/9931/3291/331
Lung adenocarcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/9931/3290/331
Pancreatic carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/9931/3290/331
CellulitisInfections and infestations1/9931/3290/331
Urinary tract infectionInfections and infestations1/9931/3290/331
Post procedural infectionInfections and infestations0/9931/3290/331
Most frequent other events
Showing 10 of 154
Most frequent other events
EventRSV_annualRSV_flexible RevaccinationRSV_1dose
Injection site painGeneral disorders595/993201/329200/331
MyalgiaMusculoskeletal and connective tissue disorders337/993108/329110/331
FatigueGeneral disorders307/993101/329110/331
HeadacheNervous system disorders192/99372/32981/331
ArthralgiaMusculoskeletal and connective tissue disorders162/99350/32950/331
Injection site erythemaGeneral disorders99/99338/32923/331
Injection site swellingGeneral disorders77/99333/32917/331
PyrexiaGeneral disorders14/9936/3298/331
Herpes zosterInfections and infestations3/9930/3294/331
ChillsGeneral disorders6/9933/3290/331

Baseline characteristics

Age, Continuous
Age, Continuous(YEARS)RSV_annualRSV_flexible RevaccinationRSV_1doseTotal
Mean70.1 ± 6.669.9 ± 6.769.9 ± 6.770.0 ± 6.6
Sex: Female, Male
Sex: Female, Male(Participants)RSV_annualRSV_flexible RevaccinationRSV_1doseTotal
Female542182180904
Male451147151749
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)RSV_annualRSV_flexible RevaccinationRSV_1doseTotal
American Indian Or Alaska Native2002
Asian29610298496
Black Or African American198633
Other - Unspecified0011
White6762192261121
08

Study locations

46 sites
  • GSK Investigational Site
    Mobile, Alabama 36608, United States
  • GSK Investigational Site
    Phoenix, Arizona 85020, United States
  • GSK Investigational Site
    Riverside, California 92503, United States
  • GSK Investigational Site
    San Diego, California 92103, United States
  • GSK Investigational Site
    Coral Gables, Florida 33134, United States
  • GSK Investigational Site
    Fort Myers, Florida 33912-4316, United States
  • GSK Investigational Site
    Sarasota, Florida 34243, United States
  • GSK Investigational Site
    The Villages, Florida 32162, United States
  • GSK Investigational Site
    Evansville, Indiana 47714, United States
  • GSK Investigational Site
    Wichita, Kansas 67226, United States
  • GSK Investigational Site
    Richfield, Minnesota 55423, United States
  • GSK Investigational Site
    Kansas City, Missouri 64114-4859, United States
  • GSK Investigational Site
    Rochester, New York 14609-3173, United States
  • GSK Investigational Site
    Mt. Pleasant, South Carolina 29464, United States
  • GSK Investigational Site
    Spartanburg, South Carolina 29303, United States
  • GSK Investigational Site
    San Antonio, Texas 78229-6306, United States
  • GSK Investigational Site
    Norfolk, Virginia 23502, United States
  • GSK Investigational Site
    Wenatchee, Washington 98801-2028, United States
  • GSK Investigational Site
    Pori, Satakunta 28100, Finland
  • GSK Investigational Site
    Espoo, 02230, Finland
  • GSK Investigational Site
    Helsinki, 00100, Finland
  • GSK Investigational Site
    Helsinki, 00930, Finland
  • GSK Investigational Site
    Jarvenpaa, 04400, Finland
  • GSK Investigational Site
    Kokkola, 67100, Finland
  • GSK Investigational Site
    Oulu, 90220, Finland
  • GSK Investigational Site
    Seinäjoki, 60100, Finland
  • GSK Investigational Site
    Tampere, 33100, Finland
  • GSK Investigational Site
    Turku, 20520, Finland
  • GSK Investigational Site
    Essen, North Rhine-Westphalia 45359, Germany
  • GSK Investigational Site
    Goch, North Rhine-Westphalia 47574, Germany
  • GSK Investigational Site
    Essen, 45355, Germany
  • GSK Investigational Site
    Hamburg, 20095, Germany
  • GSK Investigational Site
    Mainz, 55116, Germany
  • GSK Investigational Site
    München, 80339, Germany
  • GSK Investigational Site
    Wallerfing, 94574, Germany
  • GSK Investigational Site
    Würzburg, 97074, Germany
  • GSK Investigational Site
    Fukuoka, 812-0025, Japan
  • GSK Investigational Site
    Kumamoto, 861-4157, Japan
  • GSK Investigational Site
    Tokyo, 160-0017, Japan
  • GSK Investigational Site
    Changhua, 500, Taiwan
  • GSK Investigational Site
    Taichung, 40447, Taiwan
  • GSK Investigational Site
    Taichung, 407, Taiwan
  • GSK Investigational Site
    Taipei, 100, Taiwan
  • GSK Investigational Site
    Taipei, 104, Taiwan
  • GSK Investigational Site
    Taipei, 112, Taiwan
  • GSK Investigational Site
    Taoyuan, 333, Taiwan
09

References and documents

Publications

  • Schwarz TF, Hwang SJ, Ylisastigui P, Liu CS, Takazawa K, Yono M, Ervin JE, Andrews CP, Fogarty C, Eckermann T, Collete D, de Heusch M, De Schrevel N, Salaun B, Lambert A, Marechal C, Olivier A, Nakanwagi P, Lievens M, Hulstrom V. Immunogenicity and Safety Following 1 Dose of AS01E-Adjuvanted Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults: A Phase 3 Trial. J Infect Dis. 2024 Jul 25;230(1):e102-e110. doi: 10.1093/infdis/jiad546. PubMed 39052726 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.

Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2021 to primary completion in Jun 2022, 15 months.

Results were first posted in Dec 2023, 1 year 6 months after primary completion. A results delay was requested in Jun 2023.

Of 27 industry-sponsored phase 3 interventional studies under Respiratory Syncytial Virus Infections, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 19. This study's 15 months is above that.

Counting every sponsor, half of 32 studies reached it within 8 months; a quarter within 6 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 27, 2021
First posted
Feb 1, 2021
StartActual
Feb 15, 2021
Primary completionActual
Jun 6, 2022
CompletionEst.
Feb 19, 2027
Results delay requested
Jun 7, 2023
Results first posted
Dec 21, 2023
Last update
Sep 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
3 sites added, 3 sites removed
Show 3 added (2 Germany, 1 Finland)
  • GSK Investigational Site · Pori, Finland
  • GSK Investigational Site · Essen, Germany
  • GSK Investigational Site · Goch, Germany
Show 3 removed
  • GSK Investigational Site · Pori, Finland
  • GSK Investigational Site · Essen, Germany
  • GSK Investigational Site · Goch, Germany
Sep 28, 2026
Show all 1 update
  1. Sep 28, 2026
    3 sites added, 3 sites removed
    Show 3 added (2 Germany, 1 Finland)
    • GSK Investigational Site · Pori, Finland
    • GSK Investigational Site · Essen, Germany
    • GSK Investigational Site · Goch, Germany
    Show 3 removed
    • GSK Investigational Site · Pori, Finland
    • GSK Investigational Site · Essen, Germany
    • GSK Investigational Site · Goch, Germany
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04732871
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Feb 1, 2021
Start date
Feb 15, 2021
Primary completion
Jun 6, 2022
Completion
Feb 19, 2027 (estimated)
Results posted
Dec 21, 2023
Last update
Sep 28, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Arexvy

Start the discussion